Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLLISION RELAPSE trial in recurrent colorectal liver metastases
2022-002214-17Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil, levoleucovorin, irinotecan and 1 more in colorectal cancer liver metastasis (CRLM) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall survival. Started Mar 2023; status: active.
02
Drugs
capecitabineoxaliplatinfluorouracillevoleucovorinirinotecan
03
Conditions
colorectal cancer liver metastasis (CRLM)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2022-002214-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002214-17.